Managing Side Effects of Weight Loss Medication: What to Expect and What to Do
The gastrointestinal side effects of GLP-1 receptor agonists are the most common reason patients reduce their dose prematurely or discontinue treatment before reaching their therapeutic weight loss goal. At Curelo Care, clinical support includes proactive guidance on side effect management because patients who understand what to expect, why it happens, and what practical steps to take are substantially more likely to tolerate the titration period and achieve meaningful outcomes. This guide covers the evidence-based management of the most common side effects.
Why Gastrointestinal Side Effects Occur: The Mechanism
GLP-1 receptors are expressed throughout the gastrointestinal tract as well as in the hypothalamus. Pharmacological activation of GLP-1 receptors in the gut slows gastric emptying, reduces intestinal motility, and activates vagal afferent nerve fibres that signal to the brainstem, which can trigger nausea via the chemoreceptor trigger zone. This is not a toxic reaction; it is a direct consequence of the same pharmacological mechanism that creates satiety and reduces appetite. The side effects and the therapeutic effect share the same biological pathway.
The gastrointestinal side effects are predominantly early and dose-dependent. They are most prominent during the initial dose escalation phase and in the first four to eight weeks at each new dose level. As physiological tolerance to GLP-1 receptor activation develops over several weeks, the severity typically reduces substantially. This is why the slow dose titration schedule prescribed for semaglutide (dose increased every four weeks) and tirzepatide (dose increased every four weeks) is clinically essential: escalating more rapidly than the schedule is associated with significantly higher rates of nausea, vomiting, and treatment discontinuation.
Nausea: The Most Common Side Effect
Nausea is reported by approximately 44 percent of semaglutide-treated patients and approximately 31 percent of tirzepatide-treated patients during the titration phase. It is typically mild to moderate in severity, occurs in the days following the injection, and improves progressively over the following weeks. The following practical measures have clinical evidence or established clinical rationale for reducing nausea severity:
- Eat smaller, more frequent meals rather than three large meals. Large meal volumes exacerbate nausea by filling a stomach with already-slowed emptying.
- Eat slowly and chew thoroughly. Rapid eating increases the rate of gastric filling beyond the slowed emptying capacity.
- Avoid high-fat, heavily spiced, and strongly flavoured foods immediately after dose increases, as these slow gastric emptying further.
- Remain upright for at least one hour after eating. Lying down with a full, slow-emptying stomach significantly worsens nausea.
- Ginger-based products (ginger tea, ginger tablets) have modest evidence for antiemetic effect and are safe to use alongside GLP-1 medication.
- Inject on a day and at a time when you can rest if needed. Many patients find evening injection minimises daytime nausea.
Vomiting
Vomiting occurs in approximately 24 percent of semaglutide users and 13 percent of tirzepatide users during the titration period. Single episodes associated with dietary triggers should be managed with dietary adjustment. Repeated vomiting, or vomiting that prevents adequate fluid intake, requires clinical review: dehydration and electrolyte imbalance can develop rapidly and may require dose suspension. Patients at Curelo Care experiencing repeated vomiting should contact our clinical team.
Constipation
Constipation is reported in approximately 24 percent of tirzepatide users and is a common but under-reported side effect of GLP-1 therapy more broadly. It results from reduced intestinal motility caused by GLP-1 receptor activation in the gut. Preventive strategies include: increasing dietary fibre intake from fruit, vegetables, wholegrains, and pulses; maintaining daily fluid intake of at least 1.5 to 2 litres; and regular physical activity, which promotes intestinal motility. Over-the-counter macrogol laxatives (such as Movicol) are appropriate first-line management and are safe to use alongside GLP-1 medication.
Injection Site Reactions
Mild injection site reactions including redness, swelling, bruising, and itching are common and usually resolve within a few days. Rotating the injection site with each dose, injecting into the recommended sites (abdomen, outer thigh, or upper arm), allowing the pen to reach room temperature before injection, and pinching the skin gently before injecting all reduce the likelihood and severity of injection site reactions.
Important: Severe or persistent abdominal pain, particularly if radiating to the back, should be reported to your GP or contact the Curelo Care clinical team immediately, as acute pancreatitis is a recognised rare but serious adverse effect associated with GLP-1 receptor agonists. Similarly, any allergic reaction symptoms including rash, facial swelling, or difficulty breathing require immediate medical attention. These adverse events are uncommon but require prompt clinical assessment.
Clinical Disclaimer: This guide is for general informational purposes only and does not constitute personalised medical advice. Curelo Care is regulated by the General Pharmaceutical Council (GPhC). All weight management medication supplied by Curelo Care is provided following a structured online clinical assessment and prescriber review. If you have any questions about your treatment, please contact our clinical team.
